Introduction Acute lymphoblastic leukemia (ALL) is among the most common cancers in
children. With improvements in combination chemotherapy regimens, the overall survival …

Background Acute lymphoblastic leukemia (ALL) is a common hematological malignant
neoplasm that typically affects children. Although intense chemotherapeutic regimens have …

Metabolomics may shed light on treatment response in childhood acute lymphoblastic
leukemia (ALL), however, most assessments have analyzed bone marrow or cerebrospinal …

Acute myeloid leukemia (AML) is a clinically challenging disease with high interpatient
variability in response to chemotherapy. Despite continuing advances in treatment options …

Background End-induction minimal residual disease (MRD) is the strongest predictor of
relapse in paediatric acute lymphoblastic leukaemia (ALL), but an understanding of the …

Acute lymphoblastic leukemia (ALL) and its treatment continue to pose substantial risks. To
understand ALL more deeply, the metabolome in fasting plasma of 27 ALL patients before …

Introduction: Acute lymphoblastic leukemia (ALL) is the most prevalent childhood
malignancy. Despite high cure rates, several questions remain regarding predisposition …

Acute leukemias (AL) are aggressive neoplasms with high mortality rates. Metabolomics and
oxidative status have emerged as important tools to identify new biomarkers with clinical …

Acute leukaemia (AL) is a critical neoplasm of white blood cells. Diagnosing AL requires
bone marrow puncture procedure, which many patients do not consent to for it is invasive …

The tumor microenvironment is emerging as an important therapeutic target. Most studies,
however, are focused on the protein components, and relatively little is known of how the …